Nkarta, Inc.: stock overview

NKTXNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.14

November 20, 2026Market cap $81M

What Ploutos Investor adds for Nkarta

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 28% since Nov 5, 2026, when the 10-Q these figures come from was filed ($1.57 then, $1.14 on Nov 20, 2026). The figures date from before that move.10-Q

In short

Nkarta had revenue of $0 in the fiscal year to December 31, 2025 and a net loss of $129M. It holds more cash than debt, by $157M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$81M
71.29M shares
P/E
–
Revenue, fiscal year
$0
Net margin
–

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2019–2025 fiscal years
  • 202510-K
    Revenue$0
  • 202410-K
    Revenue$0
  • 2019
    Revenue$115.0K

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 
$81M
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 
0.4
FCF yield 
–
Earnings yield 
–

Profitability

Net margin 
–
ROIC 
-30.9%
ROIC, 5-year average 
-27.8%
ROE 
-46.1%

Growth

Sorry, we do not have enough data

for the “Growth” group

Balance sheet

Cash 
$157M
Total debt 
$72M
Of which operating leases 
$72M
Net cash 
$157M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
5.79

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+0.5%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Nkarta, Inc.
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
71.29M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Nkarta's filings show?

These are Nkarta's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NKTX

Didn't find what you were looking for?

Ask us
What is NKTX's market cap?

Nkarta, Inc.'s market cap is $81M, at a price of $1.14 on November 20, 2026 and 71.29M shares.

How much revenue does NKTX have?

Nkarta had revenue of $0 in the fiscal year to December 31, 2025.

Does NKTX pay a dividend?

No. Nkarta paid no regular dividend over the last 12 months.

Where do the figures come from?

From Nkarta, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.